PreACT™

Preeclampsia Risk Assessment at First Maternal Visit

We detect preeclampsia risk through antibody signatures – weeks before protein biomarkers appear.

Our diagnostic identifies women at elevated risk during very early pregnancy, when intervention strategies are most effective. Using standard serology that works anywhere, we're developing the first truly accessible preeclampsia screening test for global maternal health.

The Global Maternal Health Challenge

Current Screening Fails Most Women

Preeclampsia affects 5-8% of pregnancies and kills 70,000 mothers annually. Yet 95% of these deaths occur in low- and middle-income countries where current screening methods fail.

Why existing approaches don't translate globally:

Current algorithms rely on risk factors unavailable in most settings
Doppler ultrasound requires expensive equipment and specialised training
Protein biomarkers (PlGF/sFlt-1) need 11-13 weeks gestation – missing the prevention window

How PreACT Works

Antibody Signatures Reveal Risk Before Symptoms

Preeclampsia begins with abnormal placentation in early pregnancy – long before clinical signs appear. We are identifying specific antibody patterns correlated with the disease, creating a detectable signature.

Key Advantages:

Earlier than proteins: Antibodies detectable at the first visit, vs 11-13 weeks for PlGF/sFlt-1
Independent predictors: Our markers aren't correlated with traditional risk factors (weight, hypertension)
Robust detection: Antibodies are stable in serum and dried blood spot samples
Platform flexibility: Runs on basic ELISA equipment available in most labs and hospitals

Transforming the FMF Algorithm

Improving the Standard

The Fetal Medicine Foundation's preeclampsia screening algorithm is the global standard – but it underperforms in low-resource settings due to missing data.

PreACT as an FMF Module:

Complements current low-cost, high-availability risk factors
Objective biomarker in the first weeks of pregnancy
Independent, uncorrelated with other metrics
Enables screening where ultrasound and proteomics are not unavailable